Browsing Tag
dual agonist
1 post
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.